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The Utility of Neuroimaging in the Differential Diagnosis of 
Parkinsonian Syndromes
Florian Holtbernd, MD1 and David Eidelberg, MD1
1
 Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York
Abstract
The differential diagnosis of parkinsonian syndromes can be challenging, particularly in early 
disease stages. However, prognosis and therapeutic regimes are not alike in Parkinson disease and 
atypical parkinsonism, and thus a correct diagnosis at the earliest possible stage is desirable. Over 
the past two decades,magnetic resonance imaging and radiotracer-based imaging techniques have 
proven to be helpful tools to enhance the accuracy of clinical diagnosis in these disorders. Here, 
we review recent advances in neuroimaging for the differential diagnosis of parkinsonian 
syndromes.
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Parkinson disease (PD) is a progressive neurologic disease characterized by bradykinesia, 
rigidity, tremor, and postural instability. Its histopathological hallmark is the loss of 
dopaminergic cells in the substantia nigra (SN). The diagnosis of PD can be straightforward 
when patients present with the typical cardinal symptoms and respond well to dopaminergic 
treatment. However, particularly in early disease stages, symptoms often overlap with those 
observed in atypical parkinsonian syndromes (APS), such as multiple system atrophy 
(MSA), progressive supranuclear palsy (PSP), or corticobasal degeneration (CBD). Indeed, 
clinicopathological studies have found that up to 24% of patients clinically diagnosed with 
PD were classified as APS on autopsy.1 The sensitivity and specificity of clinical diagnosis 
even is lower for early-stage APS.2,3 Although the number of misclassifications can be 
reduced when strictly applying standardized criteria,1 the accuracy of early differential 
diagnosis remains suboptimal.
To date, there is no cure for PD. That said, the underlying pathology, prognosis, and 
symptomatic therapeutic regimes are not alike across the different forms of parkinsonism. 
Moreover, although the diagnosis of idiopathic PD relies on the presence of motor 
symptoms, it has become increasingly recognized that a variety of nonmotor symptoms can 
antecede motor symptoms in PD by many years.4
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A potentially disease-modifying therapy should be initiated early on in the disease course, 
preferably in the “prodromal” phase before motor symptoms emerge. Therefore, it is crucial 
to establish reliable biomarkers to distinguish PD from APS at the earliest possible stage. 
Over recent years, neuroimaging has evolved as a particularly useful tool in this regard.
Here, we review recent advances in magnetic resonance imaging (MRI) and radiotracer-
based imaging techniques in the differential diagnosis of parkinsonian syndromes.
Magnetic Resonance Imaging
The classic domain of conventional MRI is the exclusion of structural lesions that may cause 
secondary, symptomatic parkinsonism, such as normal pressure hydrocephalus, multiple 
sclerosis, or tumors. Cerebrovascular damage due to small vessel disease and infarctions, 
such as vascular parkinsonism, is perhaps the most common form of secondary 
parkinsonism, and abnormal structural MRI findings are present in up to 90 to 100% of 
these cases.5
In PD, structural MRI is usually normal, at least early in the disease course. In PSP, 
structural MRI may reveal the “hummingbird” sign on sagittal view (▶Fig. 1A) and the 
“Mickey Mouse” sign, also called “morning glory flower” sign, in the axial plane as a 
reflection of midbrain atrophy.6 Multiple system atrophy is characterized by putaminal and 
olivopontocerebellar atrophy.7 The putamen may appear hypointense on T2-weighted 
images with a concurrent hyperintense rim lateral to the putamen, most likely reflecting 
reactive micro- and astrogliosis (▶Fig. 1B).8 In addition, degeneration of pontocerebellar 
fibers can cause a hyperintense signal in the middle cerebellar peduncles (MCP) and pons 
that in some cases shows a cruciform configuration called the “hot cross bun” sign (▶Fig. 
1C).6,7 Although these structural abnormalities are highly specific and comport well with 
postmortem macroscopic findings, their sensitivity is rather low.6,9
Morphometric Magnetic Resonance Imaging
Magnetic resonance volumetry (MRV) allows for the quantitative assessment of brain 
atrophy. Magnetic resonance volumetry is performed in a semiautomated manner by 
defining a priori regions-of-interest (ROI). Employing this ROI-based approach, a variety of 
volume ratio indices have been proposed to assist in the differential diagnosis of 
parkinsonian syndromes. For example, Quattrone and colleagues10 measured volumes of the 
middle and superior cerebellar peduncles (SCP), pons, and midbrain in PSP, MSA, and PD 
patients. Subsequently, the pons to midbrain and MCP/SCP ratios were calculated. Both 
ratios were increased in PSP patients compared with the other two groups and normal 
controls. However, there was considerable overlap at the individual level. Of note, a 
combination of both ratios, termed the magnetic resonance parkinsonism index,10 provided 
excellent accuracy in identifying PSP patients. Similarly, others have reported reduced 
midbrain and SCP volumes in PSP patients, whereas MSA patients typically show 
pontocerebellar volume loss.11 In contrast, regional volumes usually are normal in PD.11,12 
It has been suggested, however, that atrophy of the SN may be present even in early-stage 
PD.13,14 That said, SN atrophy does not reliably distinguish PD from APS.15 Findings from 
MRV studies in CBD are less consistent. Atrophy of the corpus callosum and parietal 
Holtbernd and Eidelberg Page 2
Semin Neurol. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
cortices has been reported.16 However, others have found that these regional changes are not 
specific to CBD, but can also be observed in other APS.17
Brain atrophy can also be assessed at the whole-brain level. Voxel-based morphometry 
(VBM) is a fully automated and rater-independent approach that does not necessitate the a 
priori delineation of ROIs, but relies on whole-brain voxel-wise comparisons.18 Using 
VBM, several groups have reported cortical atrophy mainly in temporal associative, limbic, 
paralimbic, frontal, and parietal regions in PD.19–22 Two recent meta-analyses23,24 
investigated atrophy patterns of the cerebral white and gray matter in PSP patients. Subjects 
showed consistent white matter reductions in the pons, midbrain, and adjacent to the basal 
ganglia.23 Grey matter loss was observed in the thalamus, midbrain, basal ganglia, and 
insular and frontal cortices.24 In MSA, putaminal volume loss is common.25–27 Atrophy 
may also be revealed in the cerebellum, pons, sensorimotor, premotor, frontal, and insular 
cortices in these patients.26,28,29 In CBD, asymmetric cortical atrophy may be discerned, 
whereas subcortical atrophy is often less severe compared with other APS.30,31
Morphometric changes on VBM have been found to generally correlate well with clinical 
phenotype in both PD and APS.19,32,33 Voxel-based morphometry findings can aid in the 
differential diagnosis of idiopathic PD and APS, providing satisfactory specificity and 
sensitivity.34,35 Recent studies suggest that VBM also might be effective in distinguishing 
APS subtypes, for example, the cerebellar and parkinsonian variants of MSA.26
However, there remains substantial overlap at the individual level, and VBM is not yet 
established in routine clinical practice. Moreover, it remains to be proven whether disease-
specific patterns of cortical and subcortical atrophy can be reliably detected in very early 
disease stages when the need for a correct diagnosis is most urgent.
Diffusion Weighted Imaging
Diffusion weighted imaging (DWI) is a novel MRI technique that allows for the assessment 
of brain microstructural integrity. It measures the movement of water molecules, which is 
mainly directed along the white matter fibers. Axonal damage and cell loss, as commonly 
observed in neurodegenerative diseases, lead to an increase in molecule movement, and 
consequently, the apparent diffusion coefficient. Diffusion tensor imaging (DTI) provides 
additional quantitative information about the average diffusivity within one voxel (mean 
diffusivity) and directionality of diffusion (fractional anisotropy). Compared with 
conventional MRI techniques, DWI/DTI provides a major advantage to detect early, subtle 
structural changes that might not be apparent on conventional MRI.36
Increased mean diffusivity and reduced fractional anisotropy in the SN of PD patients 
indicate nigral cell loss, but do not differentiate PD from APS.37 The topography of apparent 
diffusion coefficient, mean diffusivity, and fractional anisotropy changes in APS is in good 
agreement with histopathological findings. For example, increased regional apparent 
diffusion coefficient values in the MCP separate MSA from PSP and PD patients with a 
sensitivity and specificity ranging between 84 to 100%.38,39 Patients with MSA regularly 
show increased mean diffusivity in the putamen compared with PSP and PD patients.40 In 
PSP, regional apparent diffusion coefficient has been found to be elevated in the midbrain 
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and globus pallidus as compared with PD and MSA patients, and increased apparent 
diffusion coefficient values in the SCP and caudate nucleus separated PSP from MSA 
patients.41 Studies exploring DWI/DTI abnormalities in CBD are scarce. One study42 
reported increased mean diffusivity in the anterior/medial thalamus and SCP in PSP 
compared with CBD patients. In contrast, the latter group exhibited increased mean 
diffusivity in the pre- and postcentral gyri. In addition, fractional anisotropy values were 
lower in the anterior cingulum in PSP compared with CBD patients. However, these 
findings are restricted to the group level, and their utility to differentiate PD from APS in 
single cases remains to be elucidated.
In summary, DWI/DTI may overcome the rather low sensitivity of conventional MRI 
measures, particularly in early-stage patients. However, longitudinal studies involving larger 
samples are warranted to confirm the promising findings from recent studies.
Imaging of Basal Ganglia Iron Deposition
Patients with PD show increased nigral iron content.43 T2*-weighted MRI allows for the in 
vivo assessment of cerebral iron deposition, and more recently, susceptibility weighted 
imaging (SWI) further improved the visualization of cerebral iron accumulation in 
neurodegenerative disorders.44,45 Indeed, numerous studies have reported increased iron 
content of the SN in PD.46 Moreover, patterns of basal ganglia iron deposition can be 
utilized to differentiate PD from APS. Iron accumulation has been reported to be increased 
in the globus pallidus and caudate nucleus in PSP compared with PD patients, and iron 
levels in the thalamus, globus pallidus, red nucleus, and substantia nigra have been found to 
be higher in PSP compared with MSA patients.45,47 A substantial increase in iron 
accumulation in the putamen is a characteristic feature of MSA, and it facilitates the 
separation between MSA and both PD and PSP patients.45,47,48
Magnetic Resonance Spectroscopy Imaging
Proton magnetic resonance spectroscopy imaging (H1-MRSI) allows for the assessment of 
marker molecules in brain energy metabolism and neuronal integrity. Particularly, the ratio 
of N-acetylaspartate (NAA) as a surrogate marker of neuronal structural integrity, and 
creatine (Cr), an indicator of energy metabolism, has been in the focus of several recent 
studies in parkinsonian syndromes.
Regionally decreased NAA/Cr ratios have been reported in PD patients, particularly in those 
showing cognitive impairment.49,50 However, findings are equivocal, and particularly in 
early disease stages NAA levels can be normal.51 In one study,52 PD patients exhibited a 
higher NAA/Cr ratio in the caudal SN compared with the rostral portion. Reversed ratios 
were observed in APS patients and normal controls. However, due to the limited sample 
size, APS subtypes (MSA, PSP, CBD) could not be differentiated, and NAA/Cr ratios did 
not differ between APS patients and healthy volunteers. Guevara et al53 observed decreased 
NAA levels in the putamen and globus pallidus in MSA and PSP patients compared with PD 
patients, and putaminal NAA levels also distinguished MSA from PSP patients.
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Although findings from these and other54,55 studies are promising and suggest a potential 
role of MRSI in the differential diagnosis of parkinsonian syndromes, more research is 
required to test the utility of H1-MRSI at the individual level.
Magnetization Transfer Imaging
Magnetization transfer imaging (MTI) assesses the energy transfer between protons that are 
highly bound to structures, such as myelin, and very mobile protons in free water. Thus, the 
magnitude of the magnetization transfer ratio (MTR) between these protons is highly 
dependent on axonal myelination. Consequently, demyelination and neurodegeneration lead 
to changes in MTR that have been used to visualize microstructural damage in the 
parkinsonian brain.
In keeping with DWI/DTI studies, microstructural damage of the SN has been reported to be 
present even in early-stage PD patients.56,57 Reduced MTR might also be observed in the 
caudate nucleus, putamen, thalamus, and in the periventricular, frontal, and parietal white 
matter.57 Limited data are available on the utility of MTR to differentiate among 
parkinsonian syndromes. Eckert et al identified several regions exhibiting distinct MTR 
changes in PD and APS.58 For example, MTR in the globus pallidus was reduced in MSA-
compared PD patients, and even lower values separated PSP from MSA patients. In the 
putamen, the lowest MTR was observed in MSA patients, distinguishing this group from PD 
subjects and healthy controls. However, putaminal MTR did not differ between MSA and 
PSP patients. Magnetization transfer ratio in the SN was lowest in PSP patients, and 
separated this group from both MSA and PD patients, and also MSA from PSP patients.
Radiotracer Imaging
Both positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) using a variety of radioactive tracers have been used to investigate 
brain function in parkinsonian syndromes. Positron emission tomography has a higher 
resolution and sensitivity compared with SPECT, whereas the latter technique is more 
widely available and less expensive. Additionally, more tracers are commercially available 
for SPECT, mitigating the need for an onsite cyclotron.
Dopaminergic Imaging
Loss of presynaptic striatal dopaminergic function is the hallmark of PD, and a large body of 
studies employing different tracers (e.g., 18F-fluorodopa [FDOPA], 123I-β-CIT, and 123I-FP-
CIT [FPCIT]) have investigated patterns of dopaminergic decline in parkinsonian 
syndromes. Dopaminergic decline typically is pronounced in the dorsal striatum, whereas 
dopaminergic function is preserved in the anterior putamen and caudate nucleus in early-
stage disease.59
Dopaminergic imaging readily distinguishes PD from essential tremor with very high 
accuracy.60 Presynaptic dopaminergic imaging is less useful in distinguishing PD from APS. 
It has been suggested that the anterior caudate to anterior striatum uptake ratio distinguishes 
PD from PSP patients, and that the posterior to anterior putamen ratio might be lower in PD 
compared with MSA patients.61 However, there was substantial overlap between MSA and 
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PD patients at the individual level in this study, and others have found that patterns of 
presynaptic dopaminergic decline are similar in PD and APS.62,63 The low accuracy of 
dopaminergic imaging to separate APS from PD is also reflected by the notion that in the 
USA and Europe, FPCIT SPECT is only approved for the differential diagnosis of PD/APS 
versus essential tremor, and to distinguish dementia with Lewy bodies from Alzheimer 
disease.64
It has been suggested that the additional use of postsynaptic dopaminergic tracers (e.g., 11C-
raclopride [RAC] and 123I-IBZM) might supplement the differential diagnosis in 
parkinsonism. Indeed, postsynaptic dopaminergic function is usually unaltered in PD,63 
whereas reduced tracer uptake is commonly observed in PSP, MSA, and CBD patients.65–67 
However, normal postsynaptic function does not rule out APS. For example, Plotkin et al65 
reported reduced RAC uptake in six of eight PSP patients, whereas sensitivity in MSA 
patients (seven of 13 patients), and particularly CBD (two of nine patients), was rather 
disappointing. Similarly, Vlaar and colleagues68 reported a sensitivity of 80% and 
specificity of only 62% to separate PD from APS based on IBZM SPECT in a cohort of 154 
parkinsonian patients. Of note, a pooled analysis of pre- and postsynaptic imaging in the 
same cohort improved diagnostic accuracy only marginally.68
In summary, dopaminergic imaging is a powerful tool to augment clinical diagnosis in cases 
in which there is doubt about the diagnosis of PD/APS versus essential tremor. In addition, 
decreasing tracer uptake correlates with disease progression and severity in PD patients.69,70 
That said, imaging of presynaptic dopaminergic function is not useful to differentiate PD 
from APS. Postsynaptic dopaminergic imaging might have some merit in this regard, but 
sensitivity is still low and normal postsynaptic tracer uptake does not rule out APS.
Metabolic Imaging
18F-fluorodeoxyglucose (FDG) PET directly assesses synaptic activity, a main contributor to 
brain metabolism. The use of FDG PET has revealed regional metabolic alterations in PD 
and APS. In PD, metabolism in the putamen and globus pallidus internus is typically 
increased, whereas parietal associative cortices show reduced glucose utilization. In contrast, 
in MSA patients, bilateral putaminal hypometabolism and reduced pontocerebellar activity 
are commonly observed. Brain metabolism in PSP patients is characterized by reduced 
activity in the premotor and motor cortices, as well as the midbrain. Asymmetric cortical 
and basal ganglia hypometabolism is a typical feature of patients with CBD.71,72 Of note, 
the accuracy of metabolic changes to distinguish among parkinsonian syndromes appears to 
be higher compared with dopaminergic imaging techniques, particularly in differentiating 
among the various APS.71
Alongside these regional analyses, PET has also been used to characterize functional brain 
networks at the whole-brain level. Principal component analysis (PCA), as a multivariate 
and purely data-driven analytic approach, renders possible the identification of such 
networks, and has been used extensively by our group and others to identify disease-specific 
abnormal functional brain networks in parkinsonian syndromes.73,74 Indeed, distinct brain 
networks specific to PD, MSA, and PSP have been identified using PCA (▶Fig. 2).73,75–78 
Tang et al have shown recently that these networks are very useful in the differential 
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diagnosis of parkinsonian syndromes.79 In this study, 167 patients with parkinsonian 
symptoms, but uncertain clinical diagnoses underwent FDG PET. Final clinical diagnosis 
was made by movement disorder specialists after an average follow-up time of 2.6 years. 
Image-based classification for idiopathic Parkinson disease had 84% sensitivity and 97% 
specificity. The PCA algorithm yielded similar accuracy in the identification of MSA (85% 
sensitivity, 96% specificity) and PSP patients (88% sensitivity, 94% specificity).
Cardiac Imaging
Autonomic dysfunction including cardiovascular dysautonomia is common in PD, and 
cardiac sympathetic denervation is present in the vast majority of patients. Loss of visceral 
sympathetic nerve function can be attributed to Lewy body inclusions in the cardiac plexus, 
and may antecede the manifestation of motor symptoms by several years.80
A variety of radiotracers, such as 123I-metaiodobenzylguanidine (MIBG), have been 
developed to visualize sympathetic cardiac denervation. A large body of studies has shown 
decreased cardiac MIBG uptake in patients with PD.81 Although autonomic dysfunction is 
also common in PSP and even more so in MSA, sympathetic innervation has been reported 
to be largely normal in these patients.82,83 That said, the utility of cardiac imaging in the 
differential diagnosis of parkinsonian syndromes has been discussed controversially. Some 
authors have reported excellent accuracy of MIBG PET to separate APS from PD,84 
whereas others have found that MIBG uptake can be reduced in some APS patients, and a 
normal MIBG SPECT does not rule out PD.81 Indeed, a recent meta-analysis including 391 
parkinsonian patients revealed that abnormal MIBG myocardial SPECT had a high 
sensitivity (87.7%), but unsatisfactory specificity (37.4%) to detect PD.85
Functional Imaging in Prodromal Parkinson Disease
As pointed out earlier, it is of great importance to initiate potentially disease-modifying 
therapies at the earliest possible stage of PD when evaluating these treatments. In recent 
years, it has become increasingly recognized that nonmotor symptoms can emerge many 
years before the onset of motor symptoms in PD. Rapid-eye-movement (REM) sleep 
behavior disorder (RBD) is a case in point. About 28 to 45% of patients with RBD go on to 
develop a parkinsonian syndrome within 5 years of diagnosis. Even higher conversion rates 
have been reported after 10 years.4
Consequently, several studies have explored dopaminergic integrity in individuals with 
idiopathic RBD, consistently reporting reduced striatal dopamine levels in these 
individuals.86,87 Moreover, reduced striatal tracer uptake in RBD patients is a risk factor for 
the subsequent development of a parkinsonian syndrome.88 Recently, we have found that the 
PD-related metabolic network (▶Fig. 2A) is abnormally expressed in individuals with 
RBD.89 In addition, high network expression was predictive of the subsequent development 
of PD and dementia with Lewy bodies in these subjects. Of note, network expression also 
separated RBD patients that were eventually diagnosed with MSA from converters to PD, 
indicating that metabolic network imaging might be useful in the very early differential 
diagnosis of parkinsonian syndromes before motor symptoms emerge.
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Conclusions
The diagnosis of PD and APS relies on the clinical exam. Although imaging techniques 
hitherto available have to be regarded as adjunct to clinical diagnosis, promising findings 
from recent studies support a significant role of neuroimaging in the differential diagnosis of 
parkinsonism.
The role of conventional structural MRI is largely limited to the exclusion of structural 
lesions causing secondary parkinsonism; DWI/DTI has higher sensitivity to discern subtle 
microstructural changes than conventional MRI, and has shown some potential in the 
separation of APS from PD. Studies employing novel MRI techniques such as H1-MRSI and 
MTI have provided promising results, but larger prospective studies are required to 
determine the merits of these techniques in the differential diagnosis of parkinsonian 
syndromes. Dopaminergic imaging is useful in differentiating PD and APS from essential 
tremor, but its utility in distinguishing PD from APS is limited.
Both structural and functional imaging, and particularly network-based metabolic imaging, 
has enhanced our understanding of parkinsonian disorders as systemic diseases causing 
widespread alterations of whole-brain circuitry. Functional alterations occur early on in the 
disease course, and highly specific networks have been identified to separate PD from APS. 
Given the need to correctly diagnose PD as early as possible, future research focusing on the 
premotor stage of PD is encouraged, and might open new avenues for the use of 
neuroimaging when clinical motor exam is yet unrevealing.
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Fig. 1. 
Structural magnetic resonance imaging in progressive supranuclear palsy (PSP) and multiple 
system atrophy (MSA). (A) T1-weighted image showing hummingbird sign (white arrow) in 
PSP 1.5 years after onset. (B) Proton density weighted image of pathologically confirmed 
MSA. Putaminal atrophy with hyperintense putaminal rim (white arrow) on the right and 
early hyperintense putaminal rim on the left 4.8 years after disease onset. (C) Right middle 
cerebellar peduncle sign (black arrowhead) and hot cross bun sign (white arrowhead) in 
pathologically confirmed MSA (T2-weighted image). (Adapted with permission from 
Massey et al. Conventional Magnetic Resonance Imaging in Confirmed Progressive 
Supranuclear Palsy and Multiple System Atrophy. Mov Disord 2012; 27:1754–1762.)
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Fig. 2. 
Disease-related spatial covariance patterns. (A) Parkinson disease-related pattern (PDRP) 
identified by spatial covariance analysis of 18F-fluorodeoxyglucose positron emission 
tomography (FDG PET) scans from 33 patients with Parkinson disease and 33 age-matched 
normal volunteer subjects. This pattern was characterized by relative metabolic increases 
(red) in the pallidum and thalamus, in the pons and cerebellum, and in the sensorimotor 
cortex. These changes covaried with metabolic decreases (blue) in the lateral premotor 
cortex and in parieto-occipital association regions. (Adapted from Ma et al. Abnormal 
metabolic network activity in Parkinson’s disease: test-rest reproducibility. J Cereb Blood 
Flow Metab 2007;27:597–605.) (B) Multiple system atrophy-related pattern (MSARP) 
identified by spatial covariance analysis of FDG PET scans from 10 patients with multiple 
system atrophy and 10 healthy controls. This pattern was characterized by covarying 
metabolic decreases (blue) in the putamen and the cerebellum. (Adapted with permission 
from Eckert et al. Abnormal Metabolic Networks in Atypical Parkinsonism. Mov Disord 
2008;23:727–733.) (C) Progressive supranuclear palsy-related pattern (PSPRP) identified by 
spatial covariance analysis of FDG PET scans from 10 patients with progressive 
supranuclear palsy and 10 healthy controls. This pattern was characterized by covarying 
metabolic decreases (blue) in the medial prefrontal cortex, the frontal eye fields, the 
ventrolateral prefrontal cortex, the caudate nuclei, the medial thalamus, and the upper 
brainstem. (Adapted with permission from Eckert et al. Abnormal Metabolic Networks in 
Atypical Parkinsonism. Mov Disord 2008;23:727–733.) (The covariance maps were overlaid 
on T1-weighted magnetic resonance-template images. Voxels with positive region weights 
[metabolic increases] are color-coded red and those with negative region weights [metabolic 
decreases] are color-coded blue.)
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